Patent: 9,879,325
✉ Email this page to a colleague
Summary for Patent: 9,879,325
Title: | Method for predicting the responsiveness a patient to a treatment with an anti-CD20 antibody |
Abstract: | The present invention relates to a method for predicting the responsiveness of a patient to a treatment with an anti-CD20 antibody, said method comprising measuring the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in B cells obtained from said patient. |
Inventor(s): | Chiche; Johanna (Nice, FR), Thieblemont; Catherine (Paris, FR), Ricci; Jean-Ehrland (Nice, FR) |
Assignee: | ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DIDEROT (PARIS VII) (Paris, FR) UNIVERSITE DE NICE--SOPHIA ANTIPOLIS (Nice, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (Paris, FR) |
Application Number: | 15/121,864 |
Patent Claims: | see list of patent claims |
Details for Patent 9,879,325
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2034-03-03 |
Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 10/26/2009 | ⤷ Try a Trial | 2034-03-03 |
Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 04/01/2011 | ⤷ Try a Trial | 2034-03-03 |
Novartis Pharmaceuticals Corporation | KESIMPTA | ofatumumab | Injection | 125326 | 08/20/2020 | ⤷ Try a Trial | 2034-03-03 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |